del(12)(p10) | Cancer Search

To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)

129 sites for NCT04551066

del(11)(q10), +27 more biomarkers

Myelofibrosis Transformation in Essential Thrombocythemia, +2 more conditions

parsaclisib, +1 more drug

targeted therapy

To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

144 sites for NCT04551053

del(11)(q10), +27 more biomarkers

Myelofibrosis

parsaclisib, +1 more drug

targeted therapy

A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

143 sites for NCT04576156

del(11)(q10), +27 more biomarkers

Myelofibrosis

imetelstat, +1 more drug

targeted therapy

Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis

190 sites for NCT04468984

del(11)(q10), +27 more biomarkers

Myelofibrosis Transformation in Essential Thrombocythemia, +2 more conditions

navitoclax, +1 more drug

targeted therapy

Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis

166 sites for NCT04472598

del(11)(q10), +27 more biomarkers

Myelofibrosis

navitoclax, +1 more drug

targeted therapy

A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis

127 sites for NCT03165734

del(11)(q10), +27 more biomarkers

Myelofibrosis Transformation in Essential Thrombocythemia, +2 more conditions

pacritinib

targeted therapy